Gilead's Immunomedics settles over-hyped ASCO data mishap for $4M

What started with a stock-pumping promise for a major ASCO update from Immunomedics execs on new data for its potential breast cancer drug, ended with ASCO kicking the company out of the meeting that year, while explaining that the data were old and previously presented at an industry event.